New guidance to help NHS and UK industry benefit patient
This article was originally published in Scrip
Executive Summary
New guidance on joint working from the Association of the British Pharmaceutical Industry (ABPI) should clarify what its code of practice allows in terms of joint working with the National Health Service (NHS). It stipulates that any agreements must focus on delivering patient benefit.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.